6063.T
6063.T operates in the healthcare sector, providing pharmaceutical products and related services.
Business. 6063.T operates in the healthcare sector, providing pharmaceutical products and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6063.T operates in the healthcare sector, providing pharmaceutical products and related services.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2,491,423,000, significantly exceeding its total liabilities of ¥1,926,647,000, resulting in a current ratio of 1.9. This liquidity is further supported by a low debt-to-equity ratio of 0.57, indicating a conservative capital structure. The company's return on equity of 5.4% and return on assets of 2.67% suggest moderate profitability relative to its equity and asset base.
In terms of profitability, the company's operating income of ¥113,397,000 and net income of ¥101,887,000 reflect a gross margin of 23.5% and an operating margin of 3.05%. These figures are in line with the industry's preferred metrics, which emphasize gross and operating margins as key indicators of operational efficiency. The company's financial performance is supported by a robust revenue base of ¥3,714,674,000, with a gross profit of ¥871,980,000.
The company's revenue is primarily concentrated in its core pharmaceutical operations, with no significant geographic diversification reported in the available data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, which is subject to regulatory and pricing pressures.
Looking ahead, the company is projected to maintain its revenue trajectory, with no significant changes expected in the near term. The company's operating cash flow of ¥295,747,000 and free cash flow of ¥90,047,000 indicate a strong ability to fund operations and invest in growth. Capital expenditures of ¥37,246,000 suggest a modest investment in infrastructure and expansion.
The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of dilution potential and the conservative capital structure further support the company's financial stability. The company's financial health is also reinforced by its strong cash reserves and low debt levels.
Recent financial filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial position. The company's performance remains consistent with its historical trends, and there are no indications of near-term volatility or strategic shifts.
- 6063.T maintains a strong liquidity position with cash and equivalents significantly exceeding total liabilities.
- The company's conservative capital structure, as indicated by a low debt-to-equity ratio, supports financial stability.
- Moderate profitability metrics suggest the company is performing in line with industry standards.
- Revenue concentration in core pharmaceutical operations may expose the company to specific market risks.
- The company is projected to maintain its revenue trajectory with no significant changes expected in the near term.
- Low liquidity and dilution risks, along with no immediate filing-based flags, indicate a stable financial position.
- **margin_outlook_rationale**: The company's gross and operating margins are expected to remain stable, supported by consistent revenue and cost management.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6063.T Market data — financials · 2026-05-27
- Emergency Assistance Japan Co Ltd Market data — analyst estimates · 2026-05-27